Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Insmed Incorporated - Common Stock (NQ:INSM)

133.71 -2.62 (-1.92%)
Streaming Delayed Price Updated: 2:57 PM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insmed Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Assessing Insmed: Insights From 20 Financial Analysts ↗
 
Via Benzinga
News headline image
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week ↗
The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy. 
Via Stocktwits
News headline image
Nvidia To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
Insmed Announces FDA Approval For Drug To Treat Chronic Lung Disease ↗
Via Stocktwits
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
What Does the Market Think About Insmed? ↗
 
Via Benzinga
News headline image
How Do Investors Really Feel About Insmed? ↗
 
Via Benzinga
News headline image
Insmed Stock Closes At Nearly 25-Year High As Analysts Get Bullish On FDA Nod For Lung Disease Drug: Retail Traders Ecstatic ↗
Insmed shares surged after U.S. regulators approved Brinsupri, the first treatment for non-cystic fibrosis bronchiectasis. 
Via Stocktwits
News headline image
FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease ↗
The FDA approves Insmed's Brinsupri for NCFB, cutting exacerbations and slowing the decline of lung function in Phase 3 trial patients. 
Via Benzinga
News headline image
Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approval ↗
Insmed stock hit a record high Tuesday after the FDA approved its drug, brensocatib, for patients with a lung condition. 
Via Investor's Business Daily
News headline image
$100 Invested In Insmed 10 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
Via Investor Brand Network
Topics Government
News headline image
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
EQNX::TICKER_START (NASDAQ:SNGX),(NYSE:PFE),(NYSE:MRK),(NYSE:BMY),(NASDAQ:INSM) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Government
News headline image
Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work? ↗
Shares are trading at a 25-year high ahead of what could be the first approval for a drug with a massive pipeline in front of it. 
Via Investor's Business Daily
News headline image
Cramer Says Tesla Dominates While Ouster Is 'Too Speculative' ↗
Jim Cramer advises against investing in Tempus AI due to its ongoing losses and suggests Pan American as a profitable alternative. Insmed is also considered speculative while the only viable option for... 
Via Benzinga
Topics Artificial Intelligence
News headline image
A Glimpse Into The Expert Outlook On Insmed Through 12 Analysts ↗
 
Via Benzinga
News headline image
Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Russell Rebalance: 3 Stocks Ready to Move Higher
The Russell reconstitution is underway; here are three stocks that are garnering interest as stocks that could move up to the Russell 1000 
Via MarketBeat
News headline image
Oracle, AST SpaceMobile And Halliburton Are Among Top 10 Large Cap Gainers Last Week (June 9-13): Are The Others In Your Portfolio? ↗
Top 10 large-cap stocks with biggest gains last week: INSM, CRCL, ORCL, ASTS, SAIL, VG, TEM, CASY, EQNR, HAL. Have you invested in them? 
Via Benzinga
News headline image
$100 Invested In Insmed 10 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast ↗
BofA raises Insmed price target to $109 after strong TPIP data and flags FDA decision on brensocatib as a near-term share catalyst. 
Via Benzinga
News headline image
Datadog To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Deep Dive Into Insmed Stock: Analyst Perspectives (6 Ratings) ↗
 
Via Benzinga
News headline image
Dow Gains 50 Points; US Small Business Optimism Index Rises In May ↗
 
Via Benzinga
Topics Stocks
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Which stocks are gapping on Tuesday? ↗
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
News headline image
Insmed, Tesla, Casey's General Stores And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Insmed Stock Soars Pre-market After Lung Disease Drug Achieves Positive Results In Mid-Stage Trial: Retail Gets More Bullish ↗
Insmed said that it will immediately engage with the U.S. Food and Drug Administration (FDA) regarding a late-stage study design following the positive results from the mid-stage trial. 
Via Stocktwits
Topics Death
News headline image
Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia ↗
Shares look likely to break out at the open after the biotech company unveiled promising results for a pulmonary arterial hypertension treatment. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.